On Sept. 23, 2021, Novavax announced publication of complete results from a pivotal Phase 3 clinical trial of NanoFluﾙ, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix-Mﾙ adjuvant, in The Lancet Infectious Diseases.

The trial evaluated the immunogenicity and safety of NanoFlu in older adults compared to a leading U.S.-licensed quadrivalent influenza vaccine. In the complete analysis, NanoFlu was well-tolerated and produced significantly enhanced humoral and cellular immune responses versus the comparator vaccine.